Zura Bio Limited (ZURA)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on ZURA

With Tiblio's Option Bot, you can configure your own wheel strategy including ZURA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZURA
  • Rev/Share 0.0
  • Book/Share 1.4753
  • PB 3.2427
  • Debt/Equity 0.0
  • CurrentRatio 8.3967
  • ROIC -0.5374

 

  • MktCap 281528191.0
  • FreeCF/Share -0.4634
  • PFCF -6.4435
  • PE -6.0251
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.4806

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ZURA H.C. Wainwright -- Neutral -- $5 Sept. 5, 2024

News

About Zura Bio Limited (ZURA)

  • IPO Date 2023-03-21
  • Website https://zurabio.com
  • Industry Biotechnology
  • CEO Robert Lisicki
  • Employees 30
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.